Cartesian Therapeutics Inc. (RNAC) — Capital Reinvestment Ratio
Latest as of September 2024:
0.45x
Cartesian Therapeutics Inc. (RNAC) has a Capital Reinvestment Ratio of 0.45x as of September 2024, meaning it reinvests 0% of its operating cash flow ($13.69 Million) in capital expenditures ($6.20 Million). See cash generation quality of Cartesian Therapeutics Inc. to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.45x
Capex / Operating Cash Flow
Operating Cash Flow
$13.69 Million
USD
Capital Expenditures
$6.20 Million
USD
Data as of
Sep 2024
Most recent filing
Cartesian Therapeutics Inc. Capital Reinvestment Ratio (2020–2020)
This chart tracks Cartesian Therapeutics Inc.'s Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Cartesian Therapeutics Inc. (2020–2020)
Year-by-year Capital Reinvestment Ratio for Cartesian Therapeutics Inc. from 2020 to 2020. For live market cap and broader valuation context, see RNAC company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.02x | $34.88 Million | $815.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow